Prelude Therapeutics (PRLD) Other Non-Current Assets (2020 - 2026)

Prelude Therapeutics has disclosed Other Non-Current Assets across 7 years of filings, most recently posting $3.2 million for Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $3.2 million, down 20.0% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.2 million (down 20.0% YoY), and the FY2025 annual result was $110000.0, changed 0.0% from the prior year.
• Other Non-Current Assets came in at $3.2 million for Q1 2026 at Prelude Therapeutics, up from $110000.0 in the prior quarter.
• In the past five years, Other Non-Current Assets ranged from a high of $12.5 million in Q3 2023 to a low of $110000.0 in Q4 2024.
• The 5-year median for Other Non-Current Assets is $4.0 million (2022), against an average of $4.2 million.
• Across the five-year window, Other Non-Current Assets sank 97.6% in 2024 and jumped 1270.85% in 2025, its largest moves.
• Prelude Therapeutics' Other Non-Current Assets stood at $4.0 million in 2022, then changed by 0.0% to $4.0 million in 2023, then sank by 97.28% to $110000.0 in 2024, then changed by 0.0% to $110000.0 in 2025, then jumped by 2840.91% to $3.2 million in 2026.
• The last three Other Non-Current Assets figures came in at $3.2 million (Q1 2026), $110000.0 (Q4 2025), and $3.2 million (Q3 2025), per Business Quant data.